Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (172 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights include AMN Healthcare Services, Hawkins and Arthur J. Gallagher

by Zacks Equity Research

AMN Healthcare Services, Hawkins and Arthur J. Gallagher have been highlighted in this Screen of the Week article.

Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.

Reasons to Retain Intuitive Surgical (ISRG) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Tirthankar Chakraborty headshot

3 Top Stocks to Invest In for Solid Earnings Growth

by Tirthankar Chakraborty

Invest in stocks like AMN Healthcare Services (AMN), Hawkins (HWKN) & Arthur J. Gallagher (AJG) at the moment for super earnings growth.

AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $103.47, marking a -1% move from the previous day.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.

QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing

by Zacks Equity Research

According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.

HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

Philips (PHG) Ties Up With Nuvo Group to Boost Maternal Care

by Zacks Equity Research

Philips (PHG) collaborates with Nuvo to develop maternity care services with digital solutions and eco-system building in rural areas

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care

by Zacks Equity Research

Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.

Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

by Zacks Equity Research

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails

by Zacks Equity Research

Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment toward clinical studies. However, limited commercial expertise is a woe.

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

by Zacks Equity Research

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Reasons to Add Allscripts (MDRX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

Catalent's (CTLT) New Project Completion Expands Global Footprint

by Zacks Equity Research

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

Cardinal Health (CAH) Unveils the First Surgical Incise Drape

by Zacks Equity Research

Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.

AMN vs. GDRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMN vs. GDRX: Which Stock Is the Better Value Option?

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.